Skip to main content

Klinik für Strahlentherapie und Onkologie

Prof. Dr. med. Dr. Emmanouil Fokas

Publikationsverzeichnis

Inhalte auf dieser Seite: Auswahl der wichtigsten Publikationen
Gehe zu

Auswahl der wichtigsten Publikationen

  1. Liu SK, Bham SA, Fokas E, et al. Delta-like ligand 4-notch blockade and tumor radiation response. Journal of the National Cancer Institute 2011;103:1778-98.
  2. Fokas E, Im JH, Hill S, et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Research 2012;72:239-48.
  3. Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. Journal of Clinical Oncology 2014;32:1554-62.
  4. Ashton TM, Fokas E, Kunz-Schughart LA, et al. The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nature communications 2016;7:12308.
  5. Azad A, Yin Lim S, D'Costa Z,…., Fokas E. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Molecular Medicine 2017;9:167-80.
  6. Fokas E, Ströbel P, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy as prognostic factor and individual-level surrogate for disease-free survival in rectal cancer. Journal of the National Cancer Institute 2017;109(12). 
  7. D'Costa Z, Jones K, Azad A, van Stiphout R, Lim SY, …, Fokas E. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. Cancer Research 2017;77:5952-5962.
  8. Kitz J*, Fokas E*, Beissbarth T, et al. The plane of total mesorectal excision is prognostic in rectal cancer: Results of the CAO/ARO/AIO-04 open-label, randomized, phase 3 trial. JAMA Surgery 2018;153:e181607. *joint first authors.
  9. Fokas E, Fietkau R, Hartmann A, et al. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase 3 trial. Annals of Oncology 2018;29:1521-1527.
  10. Hofheinz RD, Arnold D, Fokas E, et al. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial. Annals of Oncology 2018;29:1793-99.
  11. Fokas E, Allgauer M, Polat B, et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. Journal of Clinical Oncology 2019;37:3212-3222.
  12. Ludmir EB, Fuller CD, Moningi S,..., Rödel C, Fokas E. Sex-Based Disparities Among Cancer Clinical Trial Participants. J Natl Cancer Inst 2019;112:211-213.
  13. Diefenhardt M, Ludmir EB, Hofheinz RD,..., Fokas E. Association of sex with toxic effects, treatment adherence, and oncologic outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 randomized clinical trials of rectal cancer. JAMA Oncol 2019;6:294-6.
  14. Fokas E, Glynne-Jones R, Appelt A, ..., Rödel C. Outcome measures in multimodal rectal cancer trials. Lancet Oncology 2020;21:e252-e264.
  15. Diefenhardt M, Ludmir EB, Hofheinz RD ,.., Fokas E. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. JAMA Oncol 2020; epub ahead of print.
  16. Fokas, E., Appelt, A., Glynne-Jones, R. et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol 2021;12:805-816.
  17. Fokas E, Schlenska-Lange A, ..., Rödel C. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol 2022:8;e215455.
  18. Nicolas A, Pesic M,..., Fokas E, Greten FR. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell 2022;40:1-17.

Originalarbeiten

  1. Wang LF, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, et al. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncology Reports 2008;19:151-56.
  2. Wang LF, Fokas E, Juricko J, You A, Rose F, Pagenstecher A, et al. Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. BMC Cancer 2008;8:79.
  3. Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 2009;185:235-40.
  4. Xia P, An HX, Dang CX, Radpour R, Kohler C, Fokas E, et al. Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer. BMC Cancer 2009;9:454.
  5. Fokas E, Hanze J, Kamlah F, Eul BG, Lang N, Keil B, et al. Irradiation-dependent effects on tumor perfusion and endogenous and exogenous hypoxia markers in an A549 xenograft model. Int J Radiat Oncol Biol Phys 2010;77:1500-08.
  6. Fokas E, Henzel M, Engenhart-Cabillic R. A comparison of radiotherapy with radiotherapy plus surgery for brain metastases from urinary bladder cancer: analysis of 62 patients. Strahlenther Onkol 2010;186:565-71.
  7. Fokas E, Henzel M, Hamm K, Surber G, Kleinert G, Engenhart-Cabillic R. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. Strahlenther Onkol  2010;186:210-7.
  8. He HT, Fokas E, You A, Engenhart-Cabillic R, An HX. Siah1 proteins enhance radiosensitivity of human breast cancer cells. BMC Cancer 2010;10:403.
  9. Strassmann G, Abdellaoui S, Richter D, Bekkaoui F, Haderlein M, Fokas E, et al. Atlas-based semiautomatic target volume definition (CTV) for head-and-neck tumors. Int J Radiat Oncol Biol Phys 2010;78:1270-06.
  10. Fokas E, Henzel M, Hamm K, Surber G, Kleinert G, Engenhart-Cabillic R. Multidisciplinary treatment of brain metastases derived from colorectal cancer incorporating stereotactic radiosurgery: analysis of 78 patients. Clinical Colorectal Cancer 2011;10:121-25.
  11. Fokas E, You A, Juricko J, Engenhart-Cabillic R, An HX. Genetic alterations after carbon ion irradiation in human lung adenocarcinoma cells. International Journal of Oncology 2011;38:161-68.
  12. Liu SK, Bham SA, Fokas E, Beech J, Im J, Cho S, et al. Delta-like ligand 4-notch blockade and tumor radiation response. Journal of the National Cancer Institute 2011;103:1778-98.
  13. Strassmann G, Olbert P, Hegele A, Richter D, Fokas E, Timmesfeld N, et al. Advantage of robotic needle placement on a prostate model in HDR brachytherapy. Strahlenther Onkol 2011;187:367-72.
  14. You A, Fokas E, Wang LF, He H, Kleb B, Niederacher D, et al. Expression of the Wnt antagonist DKK3 is frequently suppressed in sporadic epithelial ovarian cancer. J Cancer Res Clin Oncol 2011;137:621-7.
  15. Fokas E, Henzel M, Hamm K, Grund S, Engenhart-Cabillic R. Brain metastases in breast cancer: analysis of the role of HER2 status and treatment in the outcome of 94 patients. Tumori 2012;98:768-74.
  16. Fokas E, Henzel M, Surber G, Kleinert G, Hamm K, Engenhart-Cabillic R. Stereotactic radiosurgery and fractionated stereotactic radiotherapy: comparison of efficacy and toxicity in 260 patients with brain metastases. Journal of Neuro-Oncology 2012;109:91-8.
  17. Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Research 2012;72:239-48.
  18. Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death & Disease 2012;3:e441.
  19. Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM, et al. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiation Oncology 2012;7:48.
  20. Prevo R*, Fokas E*, Reaper PM, Charlton PA, Pollard JR, McKenna WG, et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer biology & therapy 2012;13:1072-81. (* joint first author)
  21. Balermpas P, Michel Y, Wagenblast J, Seitz O, Sipek F, Rödel F,…., Fokas E. Nuclear NF-kappaB expression correlates with outcome among patients with head and neck squamous cell carcinoma treated with primary chemoradiation therapy. Int J Radiat Oncol Biol Phys 2013;86:785-90.
  22. Fokas E, Conradi L, Weiss C, Sprenger T, Middel P, Rau T, et al. Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study. Int J Radiat Oncol Biol Phys 2013;87:992-99.
  23. Fokas E, Eccles C, Patel N, Chu KY, Warren S, Gillies McKenna W, et al. Comparison of four target volume definitions for pancreatic cancer. Guidelines for treatment of the lymphatics and the primary tumor. Strahlenther Onkol  2013;189:407-16.
  24. Fokas E, Eccles C, Patel N, Chu KY, Warren S, McKenna WG, et al. A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy. Radiother Oncol 2013;107:200-6.
  25. Fokas E, Henzel M, Wittig A, Grund S, Engenhart-Cabillic R. Stereotactic radiosurgery of cerebral arteriovenous malformations: long-term follow-up in 164 patients of a single institution. Journal of Neurology 2013;260:2156-62.
  26. Henzel M, Fokas E, Sitter H, Wittig A, Engenhart-Cabillic R. Quality of life after stereotactic radiotherapy for meningioma: a prospective non-randomized study. Journal of Neuro-Oncology 2013;113:135-41.
  27. Warren S, Partridge M, Fokas E, Eccles CL, Brunner TB. Comparing dose-volume histogram and radiobiological endpoints for ranking intensity-modulated arc therapy and 3D-radiotherapy treatment plans for locally-advanced pancreatic cancer. Acta Oncologica 2013;52:1573-8.
  28. Balermpas P, Bauer C, Fraunholz I, Ottinger A, Wagenblast J, Stover T, Fokas E, et al. Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis. Strahlenther Onkol 2014;190: 256-62.
  29. Balermpas P, Michel Y, Wagenblast J, Seitz O, Weiss C, Rödel F,…., Fokas E. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. British Journal of Cancer 2014;110:501-09.
  30. Balermpas P, Rödel F, Liberz R, Oppermann J, Wagenblast J, Ghanaati S,…, Fokas E. Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. British Journal of Cancer 2014;111:1509-18.
  31. Balermpas P, Rödel F, Weiss C, Rödel C, Fokas E. Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. Oncoimmunology 2014;3:e27403.
  32. Fokas E, Henzel M, Surber G, Hamm K, Engenhart-Cabillic R. Stereotactic radiotherapy of benign meningioma in the elderly: clinical outcome and toxicity in 121 patients. Radiother Oncol 2014;111:457-62.
  33. Fokas E, Henzel M, Surber G, Hamm K, Engenhart-Cabillic R. Stereotactic radiation therapy for benign meningioma: long-term outcome in 318 patients. Int J Radiat Oncol Biol Phys 2014;89:569-75.
  34. Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 2014;32:1554-62.
  35. Kelly CJ, Hussien K, Fokas E, Kannan P, Shipley RJ, Ashton TM, et al. Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia. Radiother Oncol 2014;111:72-80.
  36. Fokas E, Clifford C, Spezi E, Joseph G, Branagan J, Hurt C, et al. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. Radiother Oncol 2015;117:432-37.
  37. Fokas E, Liersch T, Fietkau R, Hohenberger W, Hess C, Becker H, et al. Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: the reverse of the Will Rogers phenomenon? Cancer 2015;121:1724-27.
  38. Huang X, Taeb S, Jahangiri S, Korpela E, Cadonic I, Yu N, Fokas E, et al. miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD). Oncotarget 2015;6:22439-51.
  39. Rödel F, Wieland U, Fraunholz I, Kitz J, Rave-Frank M, Wolff HA,…., Fokas E, Rödel C. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. International Journal of Cancer 2015;136:278-88.
  40. Ashton TM, Fokas E, Kunz-Schughart LA, Folkes LK, Anbalagan S, Huether M, et al. The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nature Communications 2016;7:12308.
  41. Balermpas P, Rödel F, Rödel C, Krause M, Linge A, Lohaus F,…, Fokas E. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). International Journal of Cancer 2016;138:171-81.
  42. Diana A, Wang LM, D'Costa Z, Allen P, Azad A, Silva MA,…, Fokas E. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 2016;7:40992-1004.
  43. Diana A, Wang LM, D'Costa Z, Azad A, Silva MA, Soonawalla Z,…, Fokas E. Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 2016;7:72819-32.
  44. Fokas E, Spezi E, Patel N, Hurt C, Nixon L, Chu KY, et al. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: Analysis of the on-trial cases for the SCALOP trial. Radiother Oncol 2016;120:212-6.
  45. Holyoake DL, Ward E, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, Fokas E, et al. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. BMC Cancer 2016;16:728.
  46. Kleibeuker EA, Fokas E, Allen PD, Kersemans V, Griffioen AW, Beech J, et al. Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. Oncotarget 2016;7:76613-27.
  47. Krug D, Baumann R, Rieckmann T, Fokas E, Gauer T, Niyazi M. Situation of young radiation oncologists, medical physicists and radiation biologists in German-speaking countries : Results from a web-based survey of the Young DEGRO working group. Strahlenther Onkol 2016;192:507-15.
  48. Rödel F, Martin D, Helmke C, Balermpas P, Fokas E, Wieland U, et al. Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy. Oncotarget 2016;7:53339-49.
  49. Wang LM, Silva MA, D'Costa Z, Bockelmann R, Soonawalla Z, Liu S,…, Fokas E. The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 2016;7:4183-94.
  50. Wilson JM, Fokas E, Dutton SJ, Patel N, Hawkins MA, Eccles C, et al. ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Radiother Oncol 2016;119:306-11.
  51. Azad A, Yin Lim S, D'Costa Z, Jones K, Diana A, Sansom OJ,…, Fokas E. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Molecular Medicine 2017;9:167-80.
  52. Fotouhi Ghiam A, Taeb S, Huang X, Huang V, Ray J, Scarcello S, Fokas E, et al. Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer. Oncotarget 2017;8:4668-89.
  53. Gordon-Weeks AN, Lim SY, Yuzhalin AE, Jones K, Markelc B, Buzelli JN, Fokas E, et al. Neutrophils Promote Hepatic Metastasis Growth Through fibroblast growth factor (FGF)2-dependent Angiogenesis. Hepatology 2017.
  54. Martin D, Balermpas P, Fokas E, Rödel C, Yildirim M. Are there HIV-specific Differences for Anal Cancer Patients Treated with Standard Chemoradiotherapy in the Era of Combined Antiretroviral Therapy? Clin Oncol (R Coll Radiol) 2017;29:248-55.
  55. Mesci A, Huang X, Taeb S, Jahangiri S, Kim Y, Fokas E, et al. Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis.. Br J Cancer 2017;116: 1350-57.
  56. Yildirim M, Muller von der Grun J, Winkelmann R, Fokas E, Rödel F, Ackermann H, et al. Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters : A single-center analysis. Strahlenther Onkol 2017;193:305-14.
  57. Balermpas P, Martin D, Wieland U, Rave-Frank M, Strebhardt K, Rödel C, Fokas E*, Rödel F*. Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. Oncoimmunology 2017;6:e1288331. *joint last authors
  58. Kersemans V, Beech JS, Gilchrist S, Kinchesh P, Allen PD, Thompson J, Gomes AL, D'Costa Z, Bird L, Tullis IDC, Newman RG, Corroyer-Dulmont A, Falzone N, Azad A, Vallis KA, Sansom OJ, Muschel RJ, Vojnovic B, Hill MA, Fokas E*, Smart SC*. An efficient and robust MRI-guided radiotherapy planning approach for targeting abdominal organs and tumours in the mouse. PLoS One 2017;12:e0176693. *joint last authors
  59. Balermpas P, Rödel F, Krause M, Linge A, …, Fokas E. DKTK-ROG. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer. 2017;141:594-603.
  60. Patel N, Able S, Allen D, Fokas E, Cornelissen B, Gleeson FV, Harris AL, Vallis KA. Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using (111)In-bevacizumab. EJNMMI Re 2017;7:49.
  61. Wenger KJ, Wagner M, You SJ, Franz K, Harter PN, Burger MC, Voss M, Ronellenfitsch MW, Fokas E, Steinbach JP, Bähr O. Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncol Lett. 2017;14:1141-1146.
  62. Hill MA, Thompson JM, Kavanagh A, Tullis IDC, Newman RG, Prentice J, Beech J Gilchrist S, Smart S, Fokas E, Vojnovic B. The Development of Technology fo Effective Respiratory-Gated Irradiation Using an Image-Guided Small Animal Irradiator. Radiat Res. 2017;188:247-263.
  63. Martin D, Rödel F, Winkelmann R, Balermpas P, Rödel C, Fokas E. Peripheral Leukocytosis Is Inversely Correlated with Intratumoral CD8+ T-Cell Infiltration and Associated with Worse Outcome after Chemoradiotherapy in Anal Cancer. Front Immunol 2017;8:1225.
  64. D'Costa Z, Jones K, Azad A, van Stiphout R, Lim SY, …, Fokas E. Gemcitabine-Induced TIMP1 attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. Cancer Res 2017;77:5952-5962.
  65. Rödel F, Steinhäuser K, Kreis NN,…., Fokas E, Louwen F, Rödel C, Yuan J. Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Radiother Oncol 2018;126:214-221.
  66. Combs SE, Niyazi M, Adeberg S,…, Fokas E, et al. Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK). Cancer Med 2018;7: 1742-1749
  67. Stangl S, Tontcheva N, Sievert W, …., Fokas E, …., Multhoff G. Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 2018;142:1911-1925
  68. Kitz J*, Fokas E*, Beissbarth T, et al. The plane of total mesorectal excision is prognostic in rectal cancer: Results of the CAO/ARO/AIO-04 open-label, randomized, phase 3 trial. JAMA Surgery 2018;153:e181607. *joint first authors.
  69. Fokas E, Fietkau R, Hartmann A, et al. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase 3 trial. Annals of Oncology 2018,29:1521-1527.
  70. von den Grün JM, Hartmann A, …., Fokas E. Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials. Radiother Oncol 2018;128:557-63.
  71. Combs SE, Niyazi M, Adeberg S,…, Fokas E, et al. Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK). Cancer Med 2018;7: 1742-49.
  72. Stangl S, Tontcheva N, Sievert W,…, Fokas E, et al. Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 2018; 142:1911-25.
  73. Rödel F, Steinhauser K, Kreis NN,…, Fokas E, et al. Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Radiother Oncol 2018;126:214-21.
  74. Hoey C, Ahmed M, Fotouhi Ghiam A,…, Fokas E, et al. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy. J Transl Med 2019;17:173.
  75. Diefenhardt M, Hofheinz RD, Martin D,…, Fokas E. Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. Int J Cancer 2019;145:2282-91.
  76. von der Grün J, Winkelmann R, Meissner M,…, Fokas E, et al. Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma. Front Oncol 2019;9:20.
  77. Voss M, Franz K, Steinbach JP,…, Fokas E, et al. Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients. J Neurooncol 2019;142: 161-69.
  78. Fokas E, Allgauer M, Polat B, et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol 2019;37:3212-3222.
  79. Ludmir EB, Fuller CD, Moningi S,..., Rödel C, Fokas E. Sex-Based Disparities Among Cancer Clinical Trial Participants. J Natl Cancer Inst 2019;12:211-213.
  80. Diefenhardt M, Ludmir EB, Hofheinz RD, ...., Fokas E. Association of sex with toxic effects, treatment adherence, and oncologic outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 randomized clinical trials of rectal cancer. JAMA Oncol 2019;6:294-6.
  81. Fleischmann M, …. Fokas E,…, Tselis N. Association of Polo-Like Kinase 3 and PhosphoT273 Caspase 8 Levels With Disease-Related Outcomes Among Cervical Squamous Cell Carcinoma Patients Treated With Chemoradiation and Brachytherapy. Front Oncol 2019;9:742.
  82. Hoey C,….Fokas E,…., Liu SK. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy. J Transl Med 2019;17:173.
  83. Martin D, …, Fokas E, Rödel C. C-Reactive Protein-to-Albumin Ratio as Prognostic Marker for Anal Squamous Cell Carcinoma Treated With Chemoradiotherapy. Front Oncol 2019;9:1200.
  84. Marijnen CAM,…., Fokas E, …., Sebag-Montefiore D. International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiother Oncol 2020: epub ahead of print.
  85. Martin D, ..., Fokas E. Acute organ toxicity correlates with better clinical outcome after chemoradiotherapy in patients with anal carcinoma. Radiother Oncol 2020;149:163-73. (Pubmed-Link).
  86. Freund I, ..., Fokas E, ..., Rödel F. Fractionation-dependent radiosensitization by molecular targeting of Nek1. Cells 2020;9:1235.
  87. Martin D, ..., Fokas E. Management of anal cancer patients - a pattern of care analysis in German-speaking countries. Radiat Oncol 2020;15:122.
  88. Voss M,..., Fokas E,... , Rieger J. ERGO2: A prospective randomized trial of calorie restricted ketogenic diet and fasting in addition to re-irradiation for malignant glioma. Int J Radiat Oncol Biol Phys 2020; epub ahead of print.
  89. Diefenhardt M, Ludmir EB, Hofheinz RD..., Fokas E. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. JAMA Oncol 2020; ahead of print.
  90. Pasalic D,...,Fokas E, ..., Ludmir EB. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. Eur J Cancer. 2020 Jul 20;136:176-185.
  91. Martin D, von der Grün J, Rödel C, Fokas E. Sarcopenia is associated with hematologic toxicity during chemoradiotherapy in patients with anal carcinoma. Frontiers in Oncology 2020;10:1576.
  92. Abi Jaoude J, ..., Fokas E, ..., Ludmir EB. Performance Status Restriction in Phase III Cancer Clinical Trials. J Natl Compr Canc Netw. 2020;18:1322-1326.
  93. Wenger KJ,... , Fokas E, ..., Voss M. Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial. Cancers 2020;12:E3549.
  94. Kosmala R, Fokas E, ..., Rödel C, Polat B. Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. Eur J Cancer 2021;144:281-290.
  95. Güllülü Ö,..., Fokas E,..., Rödel F. A spatial and functional interaction of a heterotetramer Survivin-DNA-PKcs complex in DNA damage response. Cancer Res 2021;81:2304-2317.
  96. Kosmala R, Fokas E,..., Rödel C, Polat B.. Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. Eur J Cancer 2021;144:281-290.
  97. Pasalic D,..., Fokas E,..., Ludmir EB. Detecting the Dark Matter of Unpublished Clinical Cancer Studies: An Analysis of Phase 3 Randomized Controlled Trials.Mayo Clin Proc 2021;96:420-426.
  98. Divé I,... , Fokas E, Herrlinger U, Steinbach JP. Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas. Oncology 2021;99:215-224.
  99. Steidl E,..., Fokas E,..., Bähr O. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy. J Cancer Res Clin Oncol 2021; epub ahead of print.
  100. Voss M, Wenger KJ, Fokas E,..., Ronellenfitsch MW. Single-shot bevacizumab for cerebral radiation injury. BMC Neurol 2021;21:77.
  101. Arnold C, von der Grün J, Fokas E, Fleischmann M. Risk stratification by anamnesis increases SARS-CoV-2 test efficiency in cancer patients. Strahlenther Onkol 2021; accepted.
  102. Diefenhardt M, ..., Fokas E, Rödel C. Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial. Radiother Oncol 2021; 2021:164:223-231.
  103. Fokas E, Schlenska-Lange A,..., Rödel C. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol 2022;18:e215445;
  104. Martin D, Schreckenbach T,...,  Fokas E. Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG). Radiother Oncol 2022;67:233-238.
  105. Nicolas A, Pesic M,..., Fokas E, Greten FR. InflLambregts DMJ,…, Fokas E,…, Beets-Tan RGH. Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. Eur Radiol 2022 epub ahead of print. mmatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell 2022;40:1-17.
  106. Elwakeel E,... , Fokas E,... Weigert A. Disruption of prostaglandin E2 signaling in cancer-associated fibroblasts limits mammary carcinoma growth but promotes metastasis. Cancer Res 2022;82:1380-1395.
  107. Lambregts DMJ,…, Fokas E,…, Beets-Tan RGH. Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. Eur Radiol 2022;32:4991-5003
  108. Frey A,..., Fokas E,..., Fleischmann M. C-Reactive Protein to Albumin Ratio as Prognostic Marker in Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy. Biomedicines 2022;10(3):598.
  109. Zeiner PS,..., Fokas E,..., Ronellenfitsch MW. Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Glioma Patients. Neurology 2022;98:e2073-e2083.
  110. Fleischmann M,..., Fokas E,..., Tselis N. Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach. Strahlenther Onkol 2022: epub aherad of print.
  111. Luger AL,…, Fokas E,…, Ronellenfitsch MW. Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis. J Neurooncol 2022;159:243-259.
  112. Diefenhardt M, Schlenska-Lange A,..., Fokas E. Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited. Cancers 2022;14:3658.
  113. Diefenhardt M, Martin D, ..., Fokas E. Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III Trial. Cancers 2022;14:4425
  114. Fleischmann M, Mandal R,..., Fokas E, Rödel F. Prognostic impact of caspase-8, CDK9 and phospho-CDK9 (Thr 186) expression in patients with uterine cervical cancer treated with definitive chemoradiation and brachytheray. Cancers 2022;14:5500.
  115. Zimmermann M,..., Fokas E,... , Polat B. Acute toxicities of patients with locally advanced rectal cancer treated with intensified chemoradiotherapy within the CAO/ARO/AIO-12 trial: comparing conventional versus VMAT planning at a single center. Sci Rep 2022;12:21263.
  116. Diefenhardt M, Fleischmann M,..., Fokas E. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) A comparison between two multicenter randomized phase II/III trials. Radiother Oncol 2023 Feb;179:109455.
  117. O'Cathail SM, Adams R,... , Fokas E. Patient-reported outcomes in PROSPECT trial (Alliance N1048) - FOLFOX is not a panacea. Clin Transl Radiat Oncol. 2023;43:1006
  118. Schuettfort G,.., Fokas E,..., Stephan C. Differences in the course of CD4 and CD8 cells after chemoradiotherapy in PLWH with anal cancer. AIDS Res Hum Retroviruses 2023; epub ahead of print.

Übersichtsarbeiten

  1. Fokas E, Engenhart-Cabillic R, Daniilidis K, Rose F, An HX. Metastasis: the seed and soil theory gains identity. Cancer Metastasis Reviews 2007;26:705-15.
  2. Fokas E, Kraft G, An H, Engenhart-Cabillic R. Ion beam radiobiology and cancer: time to update ourselves. Biochimica et Biophysica Acta 2009;1796:216-29.
  3. Fokas E, McKenna WG, Muschel RJ. The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. Cancer Metastasis Reviews 2012;31:823-42.
  4. Fokas E, Steinbach JP, Rodel C. Biology of brain metastases and novel targeted therapies: time to translate the research. Biochimica et Biophysica Acta Rev Cancer 2013;1835:61-75.
  5. Fokas E, Weiss C, Rödel C. The role of radiotherapy in the multimodal management of esophageal cancer. Digestive Diseases 2013;31:30-7.
  6. Fokas E, Prevo R, Hammond EM, Brunner TB, McKenna WG, Muschel RJ. Targeting ATR in DNA damage response and cancer therapeutics. Cancer treatment reviews 2014;40:109-17.
  7. Fokas E, O'Neill E, Gordon-Weeks A, Mukherjee S, McKenna WG, Muschel RJ. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. Biochimica et Biophysica Acta  Rev Caner 2015;1855:61-82.
  8. Fokas E, Rödel C. Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer. Viszeralmedizin 2015;31:347-53.
  9. Fokas E, Rödel C. Targeted agents in GI radiotherapy: Clinical efficacy and side effects. Best practice & research Clinical gastroenterology 2016;30:537-49.
  10. Rödel C, Hofheinz R, Fokas E. Rectal cancer: Neoadjuvant chemoradiotherapy. Best Practice & Research Clinical Gastroenterology 2016;30:629-39.
  11. Martin D, Rödel F, Balermpas P, Rödel C, Fokas E. The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. Biochim Biophys Acta Rev Cancer. 2017;1868:221-230.
  12. Martin D, Balermpas P, Winkelmann R, Rödel F, Rödel C, Fokas E. Anal squamous  cell carcinoma - State of the art management and future perspectives. Cancer Treat Rev. 2018;65:11-21.
  13. Rödel F, Martin D,….., Fokas E. Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. Biochim Biophys Acta Rev Cancer 2019; 1871:126-37
  14. von der Grün J, Rödel F, Brandts C, Fokas E, et al. Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go? Cancers (Basel) 2019;11.
  15. Martin D, Rödel C, Fokas E. Chemoradiotherapy for anal cancer: are we as good as we think? Strahlenther Onkol 2019;195:369-73.
  16. Fokas E, Glynne-Jones R, Appelt A, Beets-Tan R, Beets G, Haustermans K, Marijnen C, Minsky BD, Ludmir E, Quirke P, Sebag-Montefiore D, Garcia-Aguilar J, Gambacorta MA, Valentini V, Buyse M, Rödel C. Outcome measures in multimodal rectal cancer trials. Lancet Oncol 2020;21:e252-e264.
  17. Martin D, Balermpas P, Gollrad J, Weiß C ..., Fokas E. RADIANCE - Radiochemo therapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clin Transl Radiat Oncol 2020;23:43-49.
  18. Güllülü Ö,..., Fokas E, Rödel F. Tumor suppressor protein p53 and inhibitor of apoptosis proteins in colorectal cancer – a promising signalling network for therapeutic interventions. Cancers 2021;13:624.
  19. Fokas, E., Appelt, A., Glynne-Jones, R. et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol 2021;12:805-816.
  20. Fleischmann M,..., Fokas E, ..., Rödel F. Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer. Cancers 2021;13:5748.
  21. Corrigan KL,...,  Fokas E, Minsky BD, Das P, Fuller CD, Ludmir EB. The Radiotherapy Quality Assurance Gap Among Phase III Cancer Clinical Trials. Radiother Oncol 2021;166:51-57.
  22. Fleischmann M, ... Fokas E,..., Rödel F. Molekulare Prädiktoren des Tumoransprechens auf eine Radiochemotherapie des Rektumkarzinoms. Der Onkologe 2021;published online.
  23. Fleischmann M,..., Rödel C, Fokas E. ACO/ARO/AIO-21 - Capecitabine-based Chemoradiotherapy in Combination with the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients: A Phase I Trial of the German Rectal Cancer Study Group. Clin Transl Radiat Oncol 2022;34:99-106.
  24. Mahmood A,..., Fokas E, Glynne-Jones R. Compliance to chemoradiation in squamous cell carcinoma of the anus. Cancer Treat Rev. 2022;106:10238.
  25. George R,..., Fokas E, Rödel F. Advances in nanotechnology-based platforms for survivin-targeted drug discovery.Expert Opin Drug Discov 2022;17:733-754.
  26. Nicolas AM,... , Fokas E, Greten FR. Preclinical orthotopic mouse model of rectal cancer and neoadjuvant therapy. STAR Protocol (Cell Press) 2022;3:101749.
  27. Fokas E,..., Rödel C. Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives. Cancer Treat Rev. 2022;112:10249

Literatur kommentiert/Lesebriefe

  1. Fokas E, Henzel M, Engenhart-Cabillic R. In reply to Weiss et al. Int J Radiat Oncol Biol Phys 2014;90:1259-60.
  2. Brunner T, Fokas E. [The results of the LAP07 trial should not be misunderstood as the end of chemoradiotherapy in pancreatic cancer]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft  [et al] 2016;192:956-8.
  3. Rodel C, Fokas E. [Inclusion of oxaliplatin in the multimodal treatment of locally advanced rectal cancer]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft  [et al] 2017;193:168-70.
  4. Martin D, Rödel C, Fokas E. [Nivolumab for pretreated metastatic anal cancer :Immune checkpoint blockade is also advised in combination with radiochemotherapy]. Strahlenther Onkol 2018;194:356-357.
  5. Martin D, Rödel C, Fokas E. [How long should we wait upon completion of chemoradiotherapy before assessment of tumor response in anal cancer?]. Strahlenther Onkol 2017;193:593-594.
  6. Fokas E, Rödel C. [Optimal fractionation regimen, and time betwee radiotherapy and operation in rectal cancer : The multicenter, randomize Stockholm III trial]. Strahlenther Onkol 2017;193:761-762.
  7. Martin D, Rödel C, Fokas E. [Nivolumab for pretreated metastatic anal cancer : Immune checkpoint blockade is also advised in combination with radiochemotherapy]. Strahlenther Onkol 2018;194: 356-7.
  8. Martin D, Rödel C, Fokas E. Chemoradiotherapy for anal cancer: are we as good as we think? Strahlenther Onkol 2019;195:369-373.
  9. Martin D, Rödel C, Fokas E. Influence of treatment compliance on the success of chemoradiotherapy for anal carcinoma. Strahlenther Onkol 2020; epub ahead of print.
  10. Fokas E, Rödel C. Preoperative treatment of rectal cancer-Critical comments on the US-American PROSPECT trial. Strahlenther Onkol 2023;199(8):781-783.
  11. Fokas E, Rödel C, Smith JJ, Garcia-Aguilar J, Buyse M, Glynne-Jones R. Disease-free survival as the endpoint in multimodal rectal cancer trials: have we got this right? Lancet Gastroenterol Hepatol 2023; epub ahead of print.

Buchbeiträge

  1. Fokas E. Stereotactic radiosurgery for the treatment of brain metastases. In: Tumors of the Central Nervous System, Volume 2: Brain metastases. Editor: M.A. Hayat. Springer, Volume 11, pp 133-140, 2013.

  2. Fokas E. Emerging targeted therapies in the management of brain metastases: Angiogenesis, BBB and Radiosensitisation. In: Tumors of the Central Nervous System, Brain metastases. Editor: M.A. Hayat. Springer, 2014.

  3. Fokas E. Emerging targeted therapies in the management of brain metastases: Breast and Lung cancer and Melanoma. In: Tumors of the Central Nervous System, Brain metastases. Editor: M.A. Hayat. Springer, 2014.

  4. Fokas E, Gambacorta MA, Rödel C, Valentini V. Radiation Therapy in Rectal Cancer. In: Radiation Oncology, Editor: F. Wenz, Springer, 2020

MENÜ